174 related articles for article (PubMed ID: 36764085)
1. Thrombin generation in real life bleeding patients on oral anticoagulants reversed (or not) with (activated) prothrombin complex concentrate.
Teissandier D; Moustafa F; Denaives A; Lebecque B; Blondonnet R; Pereira B; Monfoulet LE; Sinegre T; Schmidt J; Lebreton A
Thromb Res; 2023 Mar; 223():184-193. PubMed ID: 36764085
[TBL] [Abstract][Full Text] [Related]
2. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Perzborn E; Heitmeier S; Laux V; Buchmüller A
Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
Levy JH; Moore KT; Neal MD; Schneider D; Marcsisin VS; Ariyawansa J; Weitz JI
J Thromb Haemost; 2018 Jan; 16(1):54-64. PubMed ID: 29106076
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
[TBL] [Abstract][Full Text] [Related]
5. Roles of Four-Factor Prothrombin Complex Concentrate in the Management of Critical Bleeding.
Tanaka KA; Shettar S; Vandyck K; Shea SM; Abuelkasem E
Transfus Med Rev; 2021 Oct; 35(4):96-103. PubMed ID: 34551881
[TBL] [Abstract][Full Text] [Related]
6. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor.
Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
Thromb J; 2017; 15():6. PubMed ID: 28239301
[TBL] [Abstract][Full Text] [Related]
7. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
[TBL] [Abstract][Full Text] [Related]
8. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.
Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
Res Pract Thromb Haemost; 2017 Jul; 1(1):49-56. PubMed ID: 30046673
[TBL] [Abstract][Full Text] [Related]
9. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
[TBL] [Abstract][Full Text] [Related]
10. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
[TBL] [Abstract][Full Text] [Related]
11. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 4F-PCC and aPCC time to administration and outcomes for oral anticoagulant-related ICH.
Lin S; Cunningham B; Mullen C; Simon E; Bice D; Garlock J
Am J Emerg Med; 2022 Jun; 56():183-187. PubMed ID: 35405470
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
[TBL] [Abstract][Full Text] [Related]
15. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
[TBL] [Abstract][Full Text] [Related]
16. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban.
Dinkelaar J; Molenaar PJ; Ninivaggi M; de Laat B; Brinkman HJ; Leyte A
J Thromb Haemost; 2013 Jun; 11(6):1111-8. PubMed ID: 23578206
[TBL] [Abstract][Full Text] [Related]
17. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
[TBL] [Abstract][Full Text] [Related]
18. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
Elg M; Carlsson S; Gustafsson D
Thromb Res; 2001 Feb; 101(3):159-70. PubMed ID: 11228339
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
[TBL] [Abstract][Full Text] [Related]
20. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
